CD8A and neoplasm: As expected, the priming of GUCY2C254-262-specific CD8+ T cells by Lm-GUCY2CF255Y reduced metastatic tumor burden (Figures 5D, E) and improved survival (Figure 5F), in striking contrast to Lm-GUCY2C and Lm-GUCY2CL262I, reflecting the immunodominance of Lm epitopes in those vaccines.